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Abstract
Endothelial barrier integrity is essential for vascular homeostasis and increased vascular permeability and has been
implicated in many pathological processes, including diabetic retinopathy. Here, we investigated the effect of Rk1, a
ginsenoside extracted from sun ginseng, on regulation of endothelial barrier function. In human retinal endothelial
cells, Rk1 strongly inhibited permeability induced by VEGF, advanced glycation end-product, thrombin, or histamine.
Furthermore, Rk1 significantly reduced the vessel leakiness of retina in a diabetic mouse model. This anti-
permeability activity of Rk1 is correlated with enhanced stability and positioning of tight junction proteins at the
boundary between cells. Signaling experiments revealed that Rk1 induces phosphorylation of myosin light chain and
cortactin, which are critical regulators for the formation of the cortical actin ring structure and endothelial barrier.
These findings raise the possibility that ginsenoside Rk1 could be exploited as a novel prototype compound for the
prevention of human diseases that are characterized by vascular leakage.
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Introduction
The disruption of endothelial barrier integrity leading to
increased vasopermeability contributes to many pathological
processes, including various inflammatory diseases, acute lung
injury, and diabetic retinopathy [1,2]. Endothelial permeability is
tightly controlled by cell-cell junctions, including adherent
junctions (AJs) and tight junctions (TJs), between neighboring
endothelial cells [3,4]. TJs consist of a number of proteins,
including occludin, claudins, junctional adhesion molecules
(JAMs), and zonula occludins (ZO). Occludin, claudins, and
JAMs are major integral transmembrane proteins with adhesive
properties, and are believed to be responsible for the formation
of a tight seal between two apposing endothelial membranes of
adjacent cells [3]. Occludin and claudins form homodimeric
bridges, and ZOs connect these integral transmembrane
proteins to actin filaments [5–7]. Dynamic regulation of
perijunctional actin has been suggested to control paracellular
permeability by affecting the stability of TJs closely connected
to the actin cytoskeleton, either directly or indirectly [8,9]. In
fact, there is ample ultrastructural evidence to implicate the
temporal expression, dynamic organization, and spatial
distribution of the actin cytoskeleton in the alteration of TJ
complexes under various conditions [10]. Therefore, actin is
likely to play a critical role in modulating the integrity of TJs,
and thus, endothelial permeability.
The reorganization of the actin cytoskeleton into the cortical
actin ring and the concomitant redistribution of TJ proteins to
the cell periphery is an essential event in endothelial barrier
enhancement. Several molecules have been suggested to be
important for the formation of the cortical actin ring [11].
Phosphorylated myosin light chain (p-MLC), as well as its
kinase, myosin light chain kinase (MLCK), were observed to be
distributed in the cortical region during endothelial cell (EC)
barrier enhancement induced by sphingosine-1-phosphate
(S1P) [12,13], suggesting a potential role for spatially defined
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MLCK activation in regulating endothelial barrier function. MLC
phosphorylation at the cortical region may promote the
interaction of actin filaments and myosin, stabilizing the cortical
actin ring structures, and thereby increasing the stability of TJ
protein complexes in the cell periphery [11]. Cortactin, an F-
actin binding protein, has also been implicated in cortical actin
rearrangement [14]. Cortactin translocates from the cytoplasm
to the periphery in response to many of the same stimuli that
induce its tyrosine phosphorylation, including growth factor
treatment, integrin binding and bacterial entry. These events
also lead to activation of Rac, which are responsible for
controlling the formation of cortical actin networks. Rac
activation is required for cortactin translocation to the cell
periphery, and cortactin disperses from cortical actin networks
following treatment with the F-actin disrupting drugs. Therefore,
Cortactin translocation to the cortical actin is closely associated
with Rac-mediated actin assembly and enhanced endothelial
barrier function [13].
Diabetic retinopathy (DR) is one of the most common
vascular retinopathies and a leading cause of legal blindness in
working-age adults [15]. The earliest sign of DR is leakage
from retinal vessels due to breakdown of the blood-retinal
barrier (BRB), which is followed by retinal edema and finally
endothelial cell proliferation [16]. The BRB is a selective
endothelial barrier of well-differentiated microvessels of the
eye. The disruption of the BRB occurs during the earliest
period of vascular retinopathy, which can be recovered before
the irreversible effect of angiogenesis characteristic of
proliferative vascular retinopathy [17]. VEGF is known to play
an important role in BRB breakdown by altering tight junction
integrity and the cytoskeleton organization of endothelial cells,
leading to increased permeability during the pathogenesis of
DR [18,19]. Therapies targeting this early and reversible stage
of BRB breakdown remain to be developed.
Ginseng generally refers to the medicinal herb derived from
the roots of species of the genus Panax. Ginseng, long used in
traditional oriental medicine, is known to have a wide range of
medicinal effects, including tonic, immunomodulatory, anti-
mutagenic, adaptogenic, and anti-aging activities [20,21]. In
addition, several clinical studies have shown that Panax
ginseng improves psychological physiological function and
conditions associated with diabetes [20]. The main active
components responsible for the medicinal effects of Panax
ginseng are ginsenosides, which are triterpene saponins. The
ginsenoside composition of ginseng can vary depending on
how it is processed. Sun ginseng, recently developed by heat-
treatment at a temperature and pressure higher than those
applied to the conventional preparation of red ginseng, was
shown to contain ginsenosides enriched with Rg3, Rg5, Rk1,
Rg6, Rh2, Rh3, Rh4, and Rs3, which are either entirely absent
or present only in trace amounts in conventional white or red
ginseng [22,23].
In this study, we investigated the potential pharmacological
activities of ginsenosides in preventing the pathological loss of
vascular integrity. Surprisingly, our data show that Rk1, a
derivative of natural ginsenosides, has a strong anti-vascular
permeability activity against major pathological vascular
permeability factors, such as VEGF and Advanced Glycation
End-product (AGE). Moreover, the activity of Rk1 is correlated
with its prominent effects on the robust formation of the cortical
actin ring, which is coordinated by MLC and cortactin, and the
stabilization of TJ complexes at cell junctions.
Materials and Methods
Cell culture
Primary human retina microvascular endothelial cells
(HRECs) were purchased from the Applied Cell Biology
Research Institute and were initiated by elutriation of dispase
dissociated normal human retina tissue. These cells grown on
attachment factor-coated plates in complete medium (Cell
Systems, Kirkland, WA) or in M199 medium supplemented with
20% FBS, 3 ng/ml basic FGF (Millipore, Bedford, MA), and 10
U/ml heparin (Sigma, St. Louis, MO).
Source of ginsenosides
Ginsenosides Rb1, Rg1, Rk1 were isolated as previously
described [22]. Briefly, raw and steamed ginsengs were
refluxed with methanol for 6 h. After removal of methanol with
an evaporator, the aqueous residue was extracted with
butanol. Then, the butanol fraction was subjected to silica gel
chromatography or prep-HPLC for the isolation of ginsenoside.
Chemical structure of isolated ginsenoside was confirmed by
NMR and MS. For the qualitative and quantitative analysis of
ginsenosides, an HPLC-evaporative light scattering detector
(ELSD) was used. The purity of ginsenosides was decided by
calculation of the peak area from HPLC-ELSD data. The purity
of the ginsenosides and percentage of various ginsenosides in
mixtures used in our experiments were Rb1 (>85%), Rg1
(97%), and Rk1 (>85%). Ginsenosides were dissolved in
dimethylsulfoxide (DMSO).
[3H] sucrose permeability assay
HRECs were plated onto a Transwell filter (Corning Costar,
Acton, MA). After reaching confluence, HRECs were incubated
with M199 containing 1% FBS for 3 h and pretreated for 40 min
with or without Rb1, Rg1 or Rk1 (10 µg/ml) prior to stimulation
with VEGF (20 ng/ml) (Upstate Biotechnology, Lake Placid,
NY), Thrombin (10 units/ml) or Histamine (100 µM) (Sigma-
Aldrich, St Louis, MO) for 1 h or 5 µM AGE-BSA for 10 h.
HRECs were pretreated for 30 min with or without 1C11 (10
µg/ml) prior to stimulation with 5 µM AGE-BSA for 10 h. 50 µl
(0.8 µCi [0.0296 MBq]/ml) of [3H] sucrose (1 µCi [0.037 MBq]/
μl; Amersham Pharmacia) were added to the upper
compartment. The amount of radioactivity that diffused into the
lower compartment was determined after 30 min with a liquid
scintillation counter (PerkinElmer, Wallac, Finland). Each
experimental point was performed at least four times.
Triton X-100 extraction of TJ proteins
HRECs plated in 6-well plates were serum starved in M199
containing 1% FBS for 6 h. They were then pretreated for 40
min with or without Rk1 (10µg/ml) prior to stimulation with
VEGF (20 ng/ml) for 1 h or pretreated for 30 min with or without
1C11 (10 µg/ml) prior to stimulation with 5 µM AGE-BSA for 10
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h, and fractionated in cytoskeleton-stabilizing buffer (10 mM
HEPES [pH 7.4], 250 mM sucrose, 150 mM KCl, 1 mM EGTA,
3 mM MgCl2, 1 x protease inhibitor cocktail [Roche Diagnostics
Modular, Germany], 1 mM Na3VO4, 0.5% Triton X-100) by
centrifugation at 15,000 g for 15 min. The proteins in the Triton




Confluent HRECs were pretreated for 40 min with or without
Rk1 (10 µg/ml) prior to stimulation with 20 ng/ml VEGF (1 h) or
5 µM AGE-BSA (10 h). Confluent HRECs were treated with
Rk1 (10 µg/ml) for 30min or 1h. HRECs were fixed in 4%
paraformaldehyde for 20 min and permeabilized in 0.1% Triton
X-100/PBS, then pre-incubated with a blocking solution of PBS
containing 5% normal goat serum and 0.05% Tween-20. Cells
were then incubated for 2 h in primary antibody [mouse anti-
ZO-1, anti-ZO-2, anti-occludin (Zymed Laboratories Inc., CA),
anti-cortactin (Upstate Biotechnology, Lake Placid, NY), and
anti-pMLC2 (Cell signaling, Beverly, MA)]. Reactions were
visualized by fluorescein-conjugated anti-mouse (Vector Lab,
CA).
Confluent HRECs were pretreated for 40 min with or without
Rk1 (10 µg/ml) prior to stimulation with 20 ng/ml VEGF (1 h) or
5 µM AGE-BSA (10 h). Actin filament rearrangement was
monitored by Rhodamine Phalloidin staining, which specifically
labels F-actin. HRECs monolayers were fixed in 4%
paraformaldehyde for 20 min at room temperature, and then
washed 3 times with PBS (pH 7.4). Cells were then
permeabilized in 0.1% Triton X- 100/PBS and incubated with
0.1 mg/ml of Rhodamine Phalloidin (Molecular Probes, OR) for
1 h. All samples were observed with a fluorescence
microscope (Olympus, Olympus IX81-ZDC microscope
[Olympus, Tokyo, Japan]).
Diabetic mice were injected with 15 µg Rk1 into the vitreous
of one eye and with vehicle in the contra lateral eye. At 24 h
after injection, the mouse eyes were then enucleated and
immediately fixed in 4% PFA for 4h and washed in PBS. The
lens were then removed and the eyes were embedded in
paraffin wax for sectioning. Sections of mouse eyes were
dewaxed and then rehydrated in Tris-buffered saline (TBS).
Sections were then washed in TBS and the antigens unmasked
in 0.125% trypsin (10 min at 25 °C), washed again in TBS, and
blocked in 5% normal goat serum (20 min) in an antibody
dilution buffer consisting of TBS containing 0.01% Triton X-100.
Sections were then incubated for overnight in primary antibody
[rabbit anti-occludin (Zymed Laboratories Inc., CA)] at 4 °C.
Reactions were visualized by FITC-conjugated anti-rabbit
(Vector Lab, CA). Nuclei were counterstained with DAPI and
are seen in blue. Samples were observed with a fluorescence
microscope (Olympus, Olympus IX81-ZDC microscope
[Olympus, Tokyo, Japan).
Perfusion with FITC Dextran
Mice were injected with 50 ng VEGF alone or in combination
with 15 µg Rk1 into the vitreous of one eye and with vehicle in
the contra lateral eye. At each time point after injection, 150µl
FITC-Dextran (30 mg/ml in sterile PBS) was injected into the
left ventricle. Mice were deeply anaesthetized using ketamine/
xylazine and 40 kDa FITC-Dextran (Sigma-Aldrich, St Louis,
MO) (30 mg/ml in sterile PBS) was injected into the left
ventricle. The tracer was allowed to circulate for ~2 min and the
mouse eyes were then enucleated and immediately fixed in 4%
PFA. The mouse eyes were left overnight in PFA. The following
day, the mouse retinas were dissected in a Maltese cross-
configuration and flat-mounted onto glass slides. The mouse
retinas were then viewed by epifluorescence.
Induction of experimental diabetes
Insulin-deficient diabetes was induced in C57BL/6J mice
(8 weeks male) by a single i.p. injection of streptozotocin (STZ;
Sigma, St. Louis, MO; 2.5 mg per body-weight (BW(g)), which
was dissolved in 0.1 M sodium citrate buffer (pH 4.5) just
before injection. Age-matched normal control mice received
saline alone. Fasting blood glucose level was evaluated 3 days
later. A supplemental STZ injection (1.25 mg per BW(g)) i.p.,
was given if the fasting blood glucose was below 150 mg dl−1.
All diabetic (blood glucose level after 8 h fasting >150 mg dl−1)
and normal mice were maintained with the same diet and water
ad libitum for a total of 2 weeks. Each blood sample was taken
from the tail vein, and its glucose level was measured with
Freestyle Flash Blood Monitoring System (Nipro. Osaka,
Japan).
Diabetic mice were injected with Rk1 (1, 5, 10, 15µg) into the
vitreous of one eye and with vehicle in the contra lateral eye. At
24 h after injection, 150 µl FITC-Dextran (30 mg/ml in sterile
PBS) was injected into the left ventricle. The retinas were then
viewed by fluorescence microscopy.
Semi-quantitative RT-PCR Analysis
HRECs were pretreated for 40 min with or without Rk1 (10
µg/ml) prior to stimulation with VEGF (20 ng/ml) for 6 h or 5 µM
AGE-BSA for each time point. Total RNA was obtained from
HRECs with a TRIzol reagent kit and 0.5–5 µg RNA was used
for RT-PCR. Briefly, target RNA was converted to cDNA by
treatment with 200 units of reverse transcriptase and 500 ng of
oligo(dT) primer in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM
MgCl2, 10 mM dithiothreitol, and 1 mM dNTPs at 42 °C for 1 h.
The reaction was stopped by heating at 70 °C for 15 min. The
cDNA mixture (1 µl) was used directly for enzymatic
amplification. The polymerase chain reaction was performed in
50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 0.2 mM
dNTPs, 2.5 units of Taq DNA polymerase, and 0.1 µM of
primers. Amplification was performed in a DNA thermal cycler
(model PTC-200; MJ Research) under the following conditions:
denaturation at 94 °C for 5 min for the first cycle and for 30 sec
thereafter, annealing at 55 °C for 30 sec, and extension at 72
°C for 30 sec for 28 repetitive cycles. Final extension was at 72
°C for 10 min. All results were normalized to GAPDH mRNA.
Primers were as follows: ZO-1 5’-
CGACCATTTGAACGCAAGTT-3’ (sense) and 5’-
TCAAACTCAGGAGGCTGTGC-3’ (antisense); ZO-2 5’-
GAGGAGGTGGGAGAGAGCAG-3’ (sense) and 5’-
CTGGCTTGTGCGTTTTGATT-3’ (antisense); Occludin 5’-
ATTTATGATGAGCAGCCCCC-3’ (sense) and 5’-
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TGACCTTCCTGCTCTTCCCT-3’ (antisense); VEGF 5’-
GTGGACATCTTCCAGGAGTA-3’ (sense) and 5’-
GCGAGTCTGTGTTTTTGC-3’ (antisense); GAPDH 5’-
CGCCACAGTTTCCCGGAGGG-3’ (sense) and 5’-
CCCTCCAAAATCAAGTGGGG-3’ (antisense). Each
experimental condition was performed in quadruplicate.
Immunoprecipitation
Confluent HRECs were treated with Rk1 (0.1, 1, 5, or 10
µg/ml) for the 30min. Cellular protein from HRECs was
incubated with the anti-cortactin antibody (Upstate
Biotechnology, Lake Placid, NY) and protein A or G Sepharose
in TEG buffer (20 mM Tris-Cl, pH 7.4, 1 mM EDTA, 10%
glycerol, and 1 mM dithiothreitol containing 150 mM NaCl and
0.1% Triton X-100) at 4°C for 16 h with constant rotation.
Sepharose pellets were collected by centrifugation and washed
three times with supplemented TEG buffer. Immunoprecipitates
were analyzed by SDS-PAGE, followed by Western blot using
the indicated antibodies.
Animal studies
The mice were housed and maintained under sterile
conditions in facilities accredited by the korean Association of
Assessment and Accreditation of Laboratory Animal Care. This
study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of Yonsei University. The protocol was
approved by the Committee on the Ethics of Animal
Experiments of the University of Yonsei. All efforts were made
to minimize suffering.
Statistical Analysis
All experiments were repeated at least 3 times. Data are
presented as the means ± S.E, and statistical comparisons
between groups were performed by one-way ANOVA followed
by Tukey’s test.
Results
Rk1 inhibits VEGF-induced retinal endothelial
permeability
Vascular integrity is required for functional vasculature
maintenance and is lost in many pathological states, including
DR. Our preliminary results showed that Rk1, a major
component of SG135, which is a mixture of ginsenosides
extracted from sun ginseng, has a profound effect on the
viability of human retina endothelial cells (HRECs) as
compared to other derivatives of ginsenosides. Therefore, we
decided to investigate whether Rk1 has a protective effect on
the integrity of retina vessels using an in vitro HERCs
monolayer permeability assay. As shown in Figure 1A, Rk1
was able to inhibit VEGF-induced retinal endothelial
permeability. Interestingly, ginsenosides Rb1 and Rg1, which
have been reported to have angiogenic-related activities, had
no significant effect on VEGF-induced HREC permeability
revealing the structural specificity of Rk1 action on endothelial
cells (Figure 1B, 1C).
Increases of capillary permeability are mainly attributed to
the breakdown of the BRB. The major component of the BRB is
the TJ complex, which plays an important role in controlling the
paracellular flux of molecules. To address whether or not the
inhibitory effect of Rk1 on VEGF-induced vasopermeability is
due to changes in the levels of TJ protein expression, we
examined the transcription levels of a subset of representative
TJ proteins (ZO-1, ZO-2, and occludin). Unfortunately, the
mRNA levels of these proteins were not altered by Rk1
treatment (Figure 2A), ruling out the possibility that Rk1 directly
regulates the transcription of TJ proteins. It has been reported
that the TJ protein complex is stabilized by close connection to
the actin cytoskeleton in the membrane region and VEGF is
suggested to destabilize this complex through endocytosis [3].
Therefore, we decided to test the effect of Rk1 on the stability
of TJ proteins. In untreated confluent HRECs, TJ proteins were
predominantly present in the membrane fraction. Interestingly,
we found that VEGF treatment increased the proportion of TJ
proteins in the Triton-X-100 soluble cytosolic fraction with a
reciprocal decrease in the amount of TJ proteins in the
membrane fraction. Furthermore, we discovered that this
intracellular re-localization was blocked by Rk1 pretreatment
(Figure 2B, 2C). In order to determine the significance of this
important finding, we examined the effect of Rk1 on TJ protein
by using immunostaining techniques. Normally, confluent
HRECs display a polygonal shape and linear pattern of TJ
proteins at the cell borders and this characteristic localization of
TJ proteins is disrupted by VEGF treatment (Figure 3A, 3B).
Interestingly, pretreatment with Rk1 effectively inhibits this
VEGF effect on TJ protein localization (Figure 3A, 3B). Given
our previous observation, we wondered if Rk1 could inhibit
VEGF-induced vascular leakage in vivo. To this end, we co-
injected VEGF and Rk1 into the vitreous cavities of mice and
performed fluorescein angiography 24 h post injection. To our
surprise, we found that in deed Rk1 significantly inhibits VEGF-
induced fluorescein leakage in the mouse retina (Figure 4A,
4B). Collectively, these results demonstrate that Rk1 has a
strong capacity to prevent VEGF-induced vascular hyper-
permeability and retinal vascular leakage by stabilizing
endothelial TJ proteins at cell to cell contacts.
Rk1 prevents AGE-induced retinal endothelial
permeability
The formation of Advanced Glycation End-product (AGE)
promoted by hyperglycemia has been suggested to be
important in the development of DR by increasing vessel
leakiness [24,25]. Therefore, we sought to determine whether
Rk1 had an effect on AGE-induced vascular hyper-
permeability. AGE increased the permeability of HRECs in
vitro, an effect that was blocked by Rk1 treatment (Figure 5A).
Consistently, AGE significantly decreased the protein levels
and membrane localization of TJ proteins and these effects
were also blocked by pretreatment of Rk1 (Figures 5C, 5D, 5E,
5F). However, AGE had no significant effect on the mRNA
levels of TJ proteins (Figure 5B). Several lines of evidence
suggest that AGE contributes to the pathogenesis of DR by
inducing VEGF expression in the retina. Treatment of HRECs
with AGE increased the VEGF mRNA level within 4 h and this
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Figure 1.  Rk1, but not Rg1 or Rb1, inhibits VEGF-induced retinal endothelial permeability. .  (A) HRECs were plated onto a
Transwell filter. After reaching confluence, HRECs were pretreated for 40 min with or without Rk1 (10 µg/ml) prior to stimulation with
VEGF (20 ng/ml) for 1 h. HRECs were cultured with 50 µl (0.8 µCi/ml) of [3H] sucrose (1 µCi/µl) added to the upper compartment.
The amount of radioactivity that diffused into the lower compartment was determined after 30 min with a liquid scintillation counter.
(B) The structure of gensenosides. (C) HRECs were plated onto a Transwell filter. After reaching confluence, HRECs were
pretreated for 40 min with or without Rb1, Rg1, and Rk1 (10 µg/ml) prior to stimulation with VEGF (20 ng/ml) for 1 h. HRECs were
cultured with 50 µl (0.8 µCi/ml) of [3H] sucrose (1 µCi/µl) added to the upper compartment. The amount of radioactivity that diffused
into the lower compartment was determined after 30 min with a liquid scintillation counter. All data are presented as the mean ± S.E.
from three different experiments performed in duplicate. **, P < 0.01 vs. VEGF alone.
doi: 10.1371/journal.pone.0068659.g001
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level was sustained for up to 24 h (Figure 6A, 6B). To
determine whether AGE-induced vascular hyper-permeability is
due to the expression of VEGF, we treated cells with VEGF
receptor 2 (VEGFR2; KDR) neutralizing antibody (1C11) before
AGE treatment. VEGFR2-neutralizing antibody inhibited the
AGE-induced HREC permeability and re-distribution of TJ
proteins from the membrane fraction to the cytosolic fraction
(Figure 6C, 6D, 6E), suggesting that VEGF expression at least
partially contributes to the AGE-induced vascular hyper-
permeability.
To further investigate whether Rk1 inhibits vascular leakage
of DR in vivo, we created a diabetic mouse (DM) model, in
which hyperglycemia is induced with streptozotocin and
measured vascular leakage using fluorescein angiography.
Streptozotocin-induced hyperglycemia caused fluorescein
leakage from retina vessels in the mice, while fluorescein was
restricted to vascular lumen in control mice (Figure 7A, 7B).
Intravitreal injection of Rk1 blocked the vascular leakage in a
DM model (Figure 7A, 7B). Moreover, streptozotocin-induced
hyperglycemia significantly decreased the level of TJ proteins
in retina, which was inhibited by Rk1 treatment (Figure 8A, 8B).
In addition, mouse retinal immunofluorescent staining revealed
a significant reduction of occludin level in DM mice compared
to control mice. The injection of Rk1 into the vitreous cavities of
DM mice was able to induce recovery levels of occludin in
retina comparable to TJ protein levels of control mice (Figure
Figure 2.  Rk1 inhibits VEGF-induced destabilization of TJ proteins.  (A) HRECs were pretreated for 40 min with or without Rk1
(10 µg/ml) prior to stimulation with VEGF (20 ng/ml) for 6 h. Total mRNAs were isolated and RT-PCR was performed with specific
primers for human ZO-1, ZO-2, and occludin. GAPDH served as an internal control. (B) Confluent HRECs were pretreated for 40
min with or without Rk1 (10 µg/ml) prior to stimulation with VEGF (20 ng/ml) for 1 h. Translocation of TJ proteins was assessed as
described in “Experimental Procedures”. The Triton X-100-insoluble and soluble fractions were subjected to SDS-polyacrylamide gel
electrophoresis followed by Western blot analysis with anti-ZO-1, anti-ZO-2, anti-occludin and anti-Actin. Blots are representative of
three independent experiments. (C) Densitometric analyses are presented as the relative ratio of tight junction proteins in
membrane and cytosol and quantified with NIH ImageJ software. Data are the mean ± S.E. **, p < 0.01 vs. Control. ##, p < 0.01 vs.
VEGF alone.
doi: 10.1371/journal.pone.0068659.g002
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8C). Taken together, these results suggest that Rk1 treatment
may be able to control BRB breakdown and vascular leakage
in DR.
Rk1 blocks stress fiber formation induced by VEGF or
AGE in HRECs
Endothelial barrier regulation critically depends on the
dynamics of the endothelial cell actin cytoskeleton organization
[3,5–7]. To further understand the molecular mechanism of Rk1
Figure 3.  Rk1 effectively inhibits localization of TJ proteins disrupted by VEGF treatment.  (A) Confluent HRECs were
pretreated for 40 min with or without Rk1 (10 µg/ml) prior to stimulation with VEGF (20 ng/ml) for 1 h. The cells were then fixed and
stained with anti-ZO-1, anti-ZO-2, and anti-occludin antibodies. Arrowheads indicate disruption of tight junction proteins. (B) Tight
junction protein intensity at cell borders was analyzed and quantified with NIH ImageJ software. Data are the mean ± S.E.
doi: 10.1371/journal.pone.0068659.g003
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in regulating endothelial cell junctions, we examined the spatial
localization of actin filaments by immunofluorescence. Control
HRECs showed marginally positioned ring-like bundles of F-
actin filaments and a few stress fibers aligned with the major
axis of the cell (Figure 9A). VEGF or AGE treatment decreased
the amount of cortical actin ring structures and increased the
actin stress fibers in the cells (Figure 9A). The re-organization
of the actin cytoskeleton in VEGF- or AGE-treated HRECs was
inhibited by Rk1 pretreatment (Figure 9A). Notably, Rk1 alone
was sufficient to induce the formation of cortical actin ring
structures at cell borders in a time-dependent manner (Figure
9B, 9C). However, the increased assembly of actin into the
cortical ring structure at regions of cell-cell contact after Rk1
treatment was not due to an overall enhancement of actin
polymerization, since the ratio of monomeric and filamentous
actin did not significantly vary after Rk1 stimulation (Figure 9D).
These results suggest that Rk1 induces the spatial re-
organization of the actin cytoskeleton rather than promoting
actin polymerization to increase cortical actin ring structure.
Since myosin function, which is regulated by
phosphorylation, is involved in the stability of the cortical actin
ring structure [12], we decide to examine the phosphorylation
Figure 4.  Rk1 inhibits vascular leakages of retina by VEGF.  (A) Mice were injected with 50 ng VEGF alone or in combination
with 15 µg Rk1 into the vitreous of one eye and with vehicle in the contra lateral eye. At indicated times after injection, 150µl FITC-
Dextran (30 mg/ml in sterile PBS) was injected into the left ventricle. The retinas were then viewed using fluorescence microscopy.
Yellow arrowheads indicate region of vascular permeability. All data are presented as the mean ± S.E. from three different
experiments performed in duplicate. (B) Quantification of FITC-dextran leakage by a multi-gauge software (Fuji). Data are the mean
± S.E.
doi: 10.1371/journal.pone.0068659.g004
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status of the MLC. Interestingly, we found that control cells had
minimal amounts of p-MLC localized to peripheral actin
bundles. Rk1 treatment dramatically increased the amount of
p-MLC co-localized with the cortical actin ring structures
(Figure 10A, 10B). Furthermore, Rk1 treatment led to
phosphorylation of MLC and maximal activation was observed
after 15 min (Figure 10C). Rk1 also increased the
phosphorylation of MLC in a concentration-dependent manner
(Figure 10D). Taken together, these results suggest that Rk1
may enhance endothelial barrier integrity by inducing the
reorganization of the actin cytoskeleton into a cortical ring
structure with co-localized p-MLC.
Rk1 induces cortactin phosphorylation
Cortactin, an actin filament-binding protein, has emerged as
a central element connecting signaling pathways with
cytoskeleton restructuring particularly during cortical ring
formation [14]. We examined the effect of Rk1 on the
phosphorylation of cortactin. Rk1 treatment significantly
increased the tyrosine phosphorylation of cortactin in a
concentration- and time-dependent manner (Figure 11A, 11B).
Furthermore, immunostaining against cortactin showed that
Rk1 induced the translocation of cortactin to the cellular
periphery, co-localizing with the cortical actin (Figure 11C). Rac
small GTPase is important in the regulation of the cortical actin
structure [14,26]. GTP bound Rac interacts with WAVE, a
WASP related polypeptide, resulting in the activation of Arp2/3
Figure 5.  Rk1 inhibits AGE-induced retinal endothelial permeability.  (A) HRECs were plated onto a Transwell filter. After
reaching confluence, HRECs were pretreated for 40 min with or without Rk1 (10 µg/ml) prior to stimulation with 5 µM AGE-BSA for
10 h. HRECs were cultured with 50 µl (0.8 µCi/ml) of [3H] sucrose (1 µCi/µl) added to the upper compartment. The amount of
radioactivity that diffused into the lower compartment was determined after 30 min by liquid scintillation counter. Data are the mean
± S.E. **, P < 0.01 vs. AGE alone. (B) HRECs were pretreated for 40 min with or without Rk1 (10 µg/ml) prior to stimulation with 5
µM AGE-BSA for 10 h. Total mRNAs were isolated and RT-PCR was performed with specific primers for human ZO-1, ZO-2, and
occludin. GAPDH served as an internal control. (C) Confluent HRECs were pretreated for 40 min with or without Rk1 (10 µg/ml)
prior to stimulation with 5 µM AGE-BSA for 10 h. Western blots were probed with anti-ZO-1, anti-ZO-2, anti-occludin and anti-Actin.
(D) Densitometric analyses are presented as the relative ratio of tight junction proteins in membrane and cytosol and quantified with
NIH ImageJ software. (E) Confluent HRECs were pretreated for 40 min with or without Rk1 (10 µg/ml) prior to stimulation with 5 µM
AGE-BSA for 10 h. The cells were then fixed and stained with anti-ZO-1, anti-ZO-2, and anti-occludin antibodies. Arrowheads
indicate disruption of tight junction proteins. (F) Tight junction protein intensity at cell borders was analyzed and quantified with NIH
ImageJ software. Data are the mean ± S.E. **, p < 0.01 vs. Control. ##, p < 0.01 vs. AGE alone.
doi: 10.1371/journal.pone.0068659.g005
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Figure 6.  AGE induces retinal endothelial permeability via expression of VEGF.  (A, B) HRECs were stimulated with 5 µM
AGE-BSA for the indicated times. Total mRNAs were isolated and RT-PCR was performed with specific primers for human VEGF.
GAPDH served as an internal control. (B) Ratio of VEGF mRNA to GAPDH mRNA. (C) HRECs were plated onto a Transwell filter.
After reaching confluence, HRECs were pretreated for 30 min with or without 1C11 (10 µg/ml) prior to stimulation with 5 µM AGE-
BSA for 10 h. HRECs were cultured with 50 µl (0.8 µCi/ml) of [3H] sucrose (1 µCi/µl) added to the upper compartment. The amount
of radioactivity that diffused into the lower compartment was determined after 30 min with a liquid scintillation counter. Data are the
mean ± S.E. **, p < 0.01 vs. AGE alone. (D) Confluent HRECs were incubated for 30 min with or without 10 µg/ml 1C11 and
stimulated with 5 µM AGE-BSA for 10 h. Translocations of TJ proteins were assessed, as described in “Experimental Procedures”.
The Triton X-100-insoluble and soluble fractions were subjected to SDS-polyacrylamide gel electrophoresis followed by Western
blot analysis with anti-ZO-1, anti-ZO-2, and anti-occludin antibodies. Blots are representative of three independent experiments. (E)
Densitometric analyses are presented as the relative ratio of tight junction proteins in membrane and cytosol and quantified with NIH
ImageJ software. Data are the mean ± S.E. **, p < 0.01 vs. control. ##, p < 0.01 vs. AGE alone.
doi: 10.1371/journal.pone.0068659.g006
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and the subsequent recruitment of cortactin to the cell cortical
area [27]. We consistently found that stimulation of HRECs with
Rk1 activated Rac, with the peak activation occurring within 5
minutes (Figure S1). Taken together, these results suggest that
cortactin translocation may be involved in the formation of the
Rk1-induced cortical actin ring formation. In order to be an
efficient therapeutic agent for the treatment of disease states,
Rk1 must be able to restore damaged endothelial cell
junctions. To investigate whether Rk1 had the ability to reverse
VEGF-induced actin stress fiber formation, we added Rk1 after
treatment of VEGF to HRECs. As shown in Figure 11D, Rk1
treatment shifted VEGF-induced actin stress fibers into cortical
actin ring structures in a dose-dependent manner. These
results suggest that Rk1 may reverse VEGF-induced vascular
leakage by promoting the formation of cortical actin ring
Rk1 inhibits thrombin or histamine-induced retinal
endothelial permeability
The vasoactive mediators thrombin and histamine have long
been known to increase vascular permeability under
inflammatory conditions in vitro and in vivo [28,29]. Endothelial
permeability induced by thrombin and histamine is
Figure 7.  The effect of Rk1 on retinal vascular leakage of a DM model. .  (A) Diabetic mice were injected with Rk1 (1, 5, 10,
15µg) into the vitreous of one eye and with vehicle in the contra lateral eye. At 24 h after injection, 150 µl FITC-Dextran (30 mg/ml in
sterile PBS) was injected into the left ventricle. The retinas were then viewed by fluorescence microscopy. Yellow arrowheads
indicate region of vascular permeability. (B) Quantification of FITC-dextran leakage by a multi-gauge software (Fuji). Data are the
mean ± S.E.
doi: 10.1371/journal.pone.0068659.g007
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accompanied by alterations in cell-cell junctions and the actin
cytoskeleton [30]. We tested whether Rk1 is also capable of
blocking thrombin or histamine-induced permeability and TJ
protein disorganization in HRECs. Thrombin and histamine
significantly increased the permeability of an HREC monolayer,
an effect that was blocked by pre-treatment with Rk1 (Figure
12A). In addition, immunostaining of the TJ protein ZO-1
revealed that Rk1 inhibits thrombin or histamine-induced
segmentation and disorganization of TJ proteins at cell borders
(Figure 12B, 12C). Taken together, these results suggest that
Rk1 may have an inhibitory effect against hyper permeability
triggered by various types of stimuli.
Discussion
More than 30 kinds of ginsenosides, the putatively active
components in ginsengs, have been identified thus far and
many individual ginsenosides have been studied with respect
to their specific pharmacological effects in various disease
models [31]. However, the structural characteristics and the
precise mechanisms by which ginsenosides deliver their
medicinal benefits have not been fully elucidated. This study
represents important work to demonstrate that a sub-fraction of
ginsenoside derivatives extracted from sun ginseng,
specifically Rk1, have a surprising effect on endothelial cell
barrier function and restoration.
Recent studies have shown that certain ginsenosides,
depending on their structures, exert dual functions in
Figure 8.  Rk1 inhibits occludin reduction of a DM model.  (A) Diabetic mice were injected with 15 µg Rk1 into the vitreous of
one eye and with vehicle in the contra lateral eye. At 24 h after injection, eye homogenate was subjected to SDS-polyacrylamide gel
electrophoresis, and immunoblotting with mouse anti-ZO-1, anti-ZO-2, and anti-occludin antibodies. (B) Densitometric analyses are
presented as the relative ratio of tight junction proteins in membrane and cytosol and quantified with NIH ImageJ software. (C)
Paraffin sections (4 µm thick) of retina were stained with anti-occludin antibodies. Nuclei were counterstained with DAPI and are
seen in blue. Yellow arrowheads indicate retina blood vessel. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear
layer. Data are the mean ± S.E. **, P < 0.01 vs. DM alone.
doi: 10.1371/journal.pone.0068659.g008
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Figure 9.  Rk1 promotes cortical actin ring formation in HRECs.  (A) Confluent HRECs were pretreated for 40 min with or
without Rk1 (10 µg/ml) prior to stimulation with 20 ng/ml VEGF (1 h) or 5 µM AGE-BSA (10 h). (B) Confluent HRECs were treated
with Rk1 (10 µg/ml) for the indicated times. The cells were then fixed and processed for immunofluorescence staining using
Rhodamine Phalloidin. Arrowheads show junctional actin, arrows point to thin bundles. (C) Cortical actin intensity was analyzed and
quantified with NIH ImageJ software. (D) Global levels of G-actin and F-actin pools were quantified by immunofluorescence in a
time course after treatment of Rk1 (10 µg/ml). HRECs were stained with DNAse1 (G-actin) and phalloidin (F-actin) and the whole
optical field quantified for each fluorophore. Values are expressed as percentage of total actin. Data are the mean ± S.E.
doi: 10.1371/journal.pone.0068659.g009
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neovascularization. Ginsenoside Rg1 promotes
neovascularization in vivo and endothelial cell proliferation,
chemo-invasion, and tubulogenesis in vitro, while Rb1, Rb2,
and Rg3 inhibit angiogenesis [32–35]. We have also
demonstrated that 20(S)-Ginsenoside Rg3 prevents endothelial
cell apoptosis via inhibition of a mitochondrial caspase pathway
[36]. Interestingly, Leung et al. have recently reported that Rb1
regulates capillary morphogenesis through binding and
activation of the oestrogen β receptor in ECs [35,37]. These
results suggest that individual ginsenosides have different
functional roles in the vasculature and have specific agonistic
or antagonistic actions depending on EC receptor context and
on the side chain moieties attached to their unique sterol
backbone. Our data show that Rk1, one of the main ingredients
of sun ginseng, enhances the endothelial barrier integrity in
HRECs, whereas both Rb1 and Rg1, which are rich in white
ginseng, have no significant effect on endothelial permeability.
Structural comparison of these ginsenosides suggests that the
precise structural characteristics of ginsenosides, such as side
chains and glycosylation at the R1 site, are essential for their
vascular functions and raise the possibility that Rk1 may
interface with a specific signaling axis in ECs to regulate
endothelial integrity. Endothelial permeability is regulated by
the balance between intracellular tension imposed by actin
stress fibers and adhesive cell-cell forces imposed by
intercellular junctions, which are stabilized by the cortical actin
ring structure [38,39]. In addition, previous studies have shown
that VEGF, thrombin, and histamine, molecules known to
increase vascular permeability, markedly increase actin stress
fiber formation [4,40], an observation that is consistent with our
data. By comparison, endothelial barrier protective factors,
such as SIP and HGF, have been shown to enhance cortical
Figure 10.  Rk1 induces phosphorylation of MLC and co-localization of pMLC with the cortical actin ring.  (A) Confluent
HRECs were treated with Rk1 (10 µg/ml) for 1h. The cells were then fixed and processed for immunofluorescence staining using
Rhodamine Phalloidin and anti-pMLC (S19) antibodies. The samples were viewed by fluorescence microscopy. Arrowheads show
junctional actin, arrows point to thin bundles and localization of pMLC. (B) Co-localization intensity of pMLC and junctional actin was
analyzed and quantified with NIH ImageJ software. (C, D) Confluent HRECs were treated with Rk1 (10 µg/ml) for indicated times
and stimulated with Rk1 (0.1, 1, 5, or 10 µg/ml) for 15 min. Western blot was performed using an antibody specific for phospho-MLC
(S19). Blot was reprobed with an anti-actin antibody to verify equal loading of protein in each. Densitometric analyses are presented
as the relative ratio of p-MLC and Actin and quantified with NIH ImageJ software. Data are the mean ± S.E. **, p < 0.01 vs. Control.
doi: 10.1371/journal.pone.0068659.g010
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Figure 11.  Rk1 induces cortactin phosphorylation.  (A, B) Confluent HRECs were treated with Rk1 (0.1, 1, 5, or 10 µg/ml) for
the indicated times. Cell lysates were subject to affinity precipitation using anti-cortactin antibody. Total cortactin indicates total
amount of active and inactive cortactin in the HRECs. Western blot was performed using an antibody specific for phospho-tyrosine
(PY) and cortactin (Cort). (C) Confluent HRECs were treated with Rk1 (10 µg/ml) for 30 min. The cells were then fixed and stained
with Rhodamine Phalloidin and anti-cortactin antibody. Arrows indicate cortactin. (D) Confluent HRECs were pretreated for 1 h with
or without VEGF (20 ng/ml) prior to stimulation with Rk1 (0.5, 1, 5, or 10 µg/ml) for 1 h. The cells were then fixed and processed for
immunofluorescence staining using Rhodamine Phalloidin. The samples were viewed by fluorescence microscopy.
doi: 10.1371/journal.pone.0068659.g011
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Figure 12.  Rk1 inhibits thrombin or histamine-induced retinal endothelial permeability.  (A) HRECs were plated onto a
Transwell filter. After reaching confluence, HRECs were pretreated for 40 min with or without Rk1 (10 µg/ml) prior to stimulation with
Thrombin (10 units/ml) or Histamine (100 µM) for 1 h. [3H] sucrose permeability assay was performed. Data are the mean ± S.E. **,
P < 0.01 vs. Thrombin or Histamine alone. (B) Confluent HRECs were pretreated for 40 min with or without Rk1 (10 µg/ml) prior to
stimulation with Thrombin (10 units/ml) or Histamine (100 µM) for 1 h. The cells were then fixed and stained with anti-ZO-1 antibody.
Arrowheads indicate disruption of ZO-1 proteins. (C) ZO-1 protein intensity at cell borders was analyzed and quantified with NIH
ImageJ software. Data are the mean ± S.E. **, P < 0.01 vs. Control. ##, p < 0.01 vs. Thrombin or Histamine alone.
doi: 10.1371/journal.pone.0068659.g012
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actin ring formation [11,41]. Notably, our results show that Rk1
blocked VEGF-induced stress fiber formation with a
concomitant increase of cortical ring formation, resulting in
reduction of permeability in ECs. Furthermore, Rk1 treatment
was found to shift the actin cytoskeleton organization from
stress fibers, which were pre-formed in response to VEGF
stimulation, towards cortical ring formation, indicating that Rk1
is capable of re-organizing the actin cytoskeleton. Rk1
treatment also enhances stability and positioning of TJ proteins
at cell-cell contacts, coincident with cortical actin ring formation.
These findings indicate that the EC barrier protective effect of
Rk1 is likely due to its ability to induce cortical actin ring
formation and subsequent stabilization of TJ complexes at cell
contact regions.
Our data also illustrate the signaling mechanism by which
Rk1 induces and stabilizes the cortical actin ring structure in
ECs. Depending on where it is activated, MLCK appears to
participate in the enhancement or disruption of endothelial
barrier integrity [11]. MLC phosphorylation at the cell periphery
correlates well with cortical actin ring formation in ECs
stimulated with EC barrier enhancers, such as S1P [12].
Furthermore, cortactin interacts with MLCK via its SH3 domain,
and this interaction is important for MLC phosphorylation and
EC barrier regulation [13]. However, MLC phosphorylation is
also required for the stress fiber formation associated with the
disruption of endothelial integrity induced by VEGF and other
endothelial permeability factors [40,42]. Therefore, coordinate
spatial regulation of MLCK and cortactin appears to be
important for the specific rearrangement of the actin
cytoskeleton and co-activation of these molecules at cell
contacts is likely to be essential for enhanced EC barrier
integrity. Notably, our data show that Rk1 increases
phosphorylation and translocation of MLC as well as cortactin
to the cell periphery, corresponding to the cortical actin ring,
while VEGF, an inducer of stress fiber formation, only activates
MLC phosphorylation (Figure S2). Furthermore, our data show
that Rk1 induces the activation of Rac GTPase in ECs.
Collectively, our findings demonstrate that the barrier
enhancing action of Rk1 is closely correlated with the cortical
actin ring formation and junctional protein stability, both of
which are critical for EC barrier formation (Figure S3).
In summary, the present study demonstrates that Rk1 is a
novel endothelial barrier enhancer, which is capable of
preventing or even reversing VEGF-induced vasopermeability
in ECs. Notably, our study shows that Rk1 blocks the EC
permeability induced not only by VEGF, but also by thrombin
and histamine, highlighting the effectiveness of Rk1 in
protecting vessel integrity. Despite the significance of
endothelial leakage in the pathogenesis of vascular diseases a
very effective pharmacological treatment has yet to be
developed. Thus, the novel EC barrier protective property of
Rk1 characterized in the current study may be valuable for the
development of pharmaceuticals that might effectively control
the pathologic vascular leakage in these diseases.
Supporting Information
Figure S1.  Rk1 induces Rac activation.  Confluent HRECs
were treated with Rk1 (10 µg/ml) for the indicated times. Cell
lysates were subject to affinity precipitation using PAK-1 (p21-
activated kinase) PBD (p21-binding domain) in recombinant
protein agarose, which specifically precipitates active Rac
(Rac-GTP). “Total Rac” indicates total amount of active and
inactive Rac in the HREC. Western blot was performed using
an antibody specific for Rac.
(TIF)
Figure S2.  VEGF induces phosphorylation of myosin light
chain.  (TIF)
Figure S3.  A schematic diagram of a proposed action
mechanism of Rk1 on vascular permeability.  (TIF)
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